KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Non-Current Assets (2018 - 2025)

Esperion Therapeutics' Non-Current Assets history spans 8 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 43.05% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $16.6 million, down 38.58%, while the annual FY2025 figure was $3.3 million, 43.05% down from the prior year.
  • Non-Current Assets reached $3.3 million in Q4 2025 per ESPR's latest filing, down from $3.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $54.6 million in Q3 2021 to a low of $1.2 million in Q1 2023.
  • Average Non-Current Assets over 5 years is $16.5 million, with a median of $5.6 million recorded in 2021.
  • Peak YoY movement for Non-Current Assets: surged 874.13% in 2022, then tumbled 97.67% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $52.6 million in 2021, then plummeted by 97.61% to $1.3 million in 2022, then skyrocketed by 276.67% to $4.7 million in 2023, then grew by 23.08% to $5.8 million in 2024, then crashed by 43.05% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Non-Current Assets are $3.3 million (Q4 2025), $3.6 million (Q3 2025), and $4.5 million (Q2 2025).